| 1 |
Lv R, Lu F, Xu S. Hsa_circ_0001361 facilitates cell progression and glycolytic metabolism in neuroblastoma via interacting with mir-490-5p to induce TRIM2 upregulation. Metab Brain Dis 2023. [PMID: 36920626 DOI: 10.1007/s11011-023-01197-4] [Reference Citation Analysis]
|
| 2 |
Guo X, Gao C, Yang DH, Li S. Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance. Drug Resist Updat 2023;67:100937. [PMID: 36753923 DOI: 10.1016/j.drup.2023.100937] [Reference Citation Analysis]
|
| 3 |
Zhang S, Jiang R, Yang M, Wang T, Chen H, Shi Y, Liu W, Huang M. Identification of a novel eighteen-gene signature of recurrent metastasis neuroblastoma. J Mol Med (Berl) 2023. [PMID: 36856811 DOI: 10.1007/s00109-023-02299-3] [Reference Citation Analysis]
|
| 4 |
Lin L, Deng C, Zhou C, Zhang X, Zhu J, Liu J, Wu H, He J. NSUN2 gene rs13181449 C>T polymorphism reduces neuroblastoma risk. Gene 2023;854:147120. [PMID: 36529349 DOI: 10.1016/j.gene.2022.147120] [Reference Citation Analysis]
|
| 5 |
Gu Y, Zhong K, Peng L, Ding W, Zeng X. TRAF4 Silencing Induces Cell Apoptosis and Improves Retinoic Acid Sensitivity in Human Neuroblastoma. Neurochem Res 2023. [PMID: 36795185 DOI: 10.1007/s11064-023-03882-3] [Reference Citation Analysis]
|
| 6 |
Han Y, Li B, Yan D, Zhou D, Yuan X, Zhao W, Zhang D, Zhang J. Combining multiple cell death pathway-related risk scores to develop neuroblastoma cell death signature. J Cancer Res Clin Oncol 2023. [PMID: 36781504 DOI: 10.1007/s00432-023-04605-5] [Reference Citation Analysis]
|
| 7 |
Hall MK, Shajahan A, Burch AP, Hatchett CJ, Azadi P, Schwalbe RA. Limited N-Glycan Processing Impacts Chaperone Expression Patterns, Cell Growth and Cell Invasiveness in Neuroblastoma. Biology (Basel) 2023;12. [PMID: 36829569 DOI: 10.3390/biology12020293] [Reference Citation Analysis]
|
| 8 |
Pakravan S, Hemmati-dinarvand M, Moghaddasi M, Fathi J, Nowrouzi-sohrabi P, Hormozi M. Hydroxytyrosol's effect on the expression of apoptosis and oxidative stress related genes in BE (2)-C neuroblastoma cell line. Gene Reports 2023. [DOI: 10.1016/j.genrep.2023.101750] [Reference Citation Analysis]
|
| 9 |
Di Francesco M, Pastorino F, Ferreira M, Fragassi A, Di Francesco V, Palange AL, Celia C, Di Marzio L, Cilli M, Bensa V, Ponzoni M, Decuzzi P. Augmented efficacy of nano-formulated docetaxel plus curcumin in orthotopic models of neuroblastoma. Pharmacol Res 2023;188:106639. [PMID: 36586642 DOI: 10.1016/j.phrs.2022.106639] [Reference Citation Analysis]
|
| 10 |
Luo J, Li Y, Zhang T, Xv T, Chen C, Li M, Qiu Q, Song Y, Wan S. Extrachromosomal circular DNA in cancer drug resistance and its potential clinical implications. Front Oncol 2022;12:1092705. [PMID: 36793345 DOI: 10.3389/fonc.2022.1092705] [Reference Citation Analysis]
|
| 11 |
Wu Y, Zhang J. Study on differentially expressed genes between stage M and stage MS neuroblastoma. Front Oncol 2022;12:1083570. [PMID: 36713522 DOI: 10.3389/fonc.2022.1083570] [Reference Citation Analysis]
|
| 12 |
Granata V, Fusco R, Setola SV, Simonetti I, Picone C, Simeone E, Festino L, Vanella V, Vitale MG, Montanino A, Morabito A, Izzo F, Ascierto PA, Petrillo A. Immunotherapy Assessment: A New Paradigm for Radiologists. Diagnostics (Basel) 2023;13. [PMID: 36673112 DOI: 10.3390/diagnostics13020302] [Reference Citation Analysis]
|
| 13 |
Ivasko SM, Anders K, Grunewald L, Launspach M, Klaus A, Schwiebert S, Ruf P, Lindhofer H, Lode HN, Andersch L, Schulte JH, Eggert A, Hundsdoerfer P, Künkele A, Zirngibl F. Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model. Front Immunol 2022;13:1023206. [PMID: 36700232 DOI: 10.3389/fimmu.2022.1023206] [Reference Citation Analysis]
|
| 14 |
Zhou Y, Gao J. A Novel Online Nomogram Established with Five Features before Surgical Resection for Predicating Prognosis of Neuroblastoma Children: A Population-Based Study. Technol Cancer Res Treat 2023;22:15330338221145141. [PMID: 36604997 DOI: 10.1177/15330338221145141] [Reference Citation Analysis]
|
| 15 |
Pulido R, Nunes-Xavier CE. Editorial: Cell and Developmental Signalling in Neuroblastoma. Front Cell Dev Biol 2022;10:1126352. [PMID: 36684434 DOI: 10.3389/fcell.2022.1126352] [Reference Citation Analysis]
|
| 16 |
Snyder BM, Lion AH, Helvie AE, Marshall MS, Ferguson MJ. Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response. Clin Case Rep 2023;11:e6779. [PMID: 36619485 DOI: 10.1002/ccr3.6779] [Reference Citation Analysis]
|
| 17 |
Liu F, Xiong QW, Wang JH, Peng WX. Roles of lncRNAs in childhood cancer: Current landscape and future perspectives. Front Oncol 2023;13:1060107. [PMID: 36923440 DOI: 10.3389/fonc.2023.1060107] [Reference Citation Analysis]
|
| 18 |
Zhou X, Wang X, Li N, Guo Y, Yang X, Lei Y. Therapy resistance in neuroblastoma: Mechanisms and reversal strategies. Front Pharmacol 2023;14:1114295. [PMID: 36874032 DOI: 10.3389/fphar.2023.1114295] [Reference Citation Analysis]
|
| 19 |
Wang X, Yang J, Bian H, Yang H. Development of A novel ferroptosis-related prognostic signature with multiple significance in paediatric neuroblastoma. Front Pediatr 2023;11:1067187. [PMID: 36911020 DOI: 10.3389/fped.2023.1067187] [Reference Citation Analysis]
|
| 20 |
Wang H, Shi B, Zhang X, Shen P, He Q, Yin M, Pan Y, Ma J. Exosomal hsa-piR1089 promotes proliferation and migration in neuroblastoma via targeting KEAP1. Pathol Res Pract 2023;241:154240. [PMID: 36436316 DOI: 10.1016/j.prp.2022.154240] [Reference Citation Analysis]
|
| 21 |
Yang X, Li J, Yang J. Promising Molecular Targets and Novel Therapeutic Approaches in Neuroblastoma. Curr Pharmacol Rep 2022. [DOI: 10.1007/s40495-022-00306-8] [Reference Citation Analysis]
|
| 22 |
Tan K, Mo J, Li M, Dong Y, Han Y, Sun X, Ma Y, Zhu K, Wu W, Lu L, Liu J, Zhao K, Zhang L, Tang Y, Lv Z. SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma. J Exp Clin Cancer Res 2022;41:352. [PMID: 36539767 DOI: 10.1186/s13046-022-02563-3] [Reference Citation Analysis]
|
| 23 |
Yang J, Han L, Sha Y, Jin Y, Li Z, Gong B, Li J, Liu Y, Wang Y, Zhao Q. A novel ganglioside-related risk signature can reveal the distinct immune landscape of neuroblastoma and predict the immunotherapeutic response. Front Immunol 2022;13:1061814. [PMID: 36605200 DOI: 10.3389/fimmu.2022.1061814] [Reference Citation Analysis]
|
| 24 |
Almeida J, Mota I, Skoda J, Sousa E, Cidade H, Saraiva L. Deciphering the Role of p53 and TAp73 in Neuroblastoma: From Pathogenesis to Treatment. Cancers (Basel) 2022;14. [PMID: 36551697 DOI: 10.3390/cancers14246212] [Reference Citation Analysis]
|
| 25 |
Chen ZF, Wu LZ, Chen ZT, Su LJ, Fu CJ. The potential mechanisms of neuroblastoma in children based on bioinformatics big data. Transl Pediatr 2022;11:1908-19. [PMID: 36643678 DOI: 10.21037/tp-22-504] [Reference Citation Analysis]
|
| 26 |
Zheng L, Li Z, Wang Z, Shen L, Liu J. The oxidative stress, mitochondrial pathway apoptosis, and the antagonistic effects of chrysophanol in SH-SY5Y cells via DTPP-induced photodynamic therapy. Photodiagnosis Photodyn Ther 2022;40:103062. [PMID: 35963528 DOI: 10.1016/j.pdpdt.2022.103062] [Reference Citation Analysis]
|
| 27 |
Hou R, Yu Y, Jiang J. Prostaglandin E2 in neuroblastoma: Targeting synthesis or signaling? Biomedicine & Pharmacotherapy 2022;156:113966. [DOI: 10.1016/j.biopha.2022.113966] [Reference Citation Analysis]
|
| 28 |
Zhang J, Han Y, Yan D, Zhou D, Yuan X, Zhao W, Zhang D. Identification of Key Genes Associated with Risk and Prognosis of Neuroblastoma. J Mol Neurosci 2022;72:2398-412. [PMID: 36443552 DOI: 10.1007/s12031-022-02087-7] [Reference Citation Analysis]
|
| 29 |
Caffarelli C, Santamaria F, Piro E, Basilicata S, Delle Cave V, Cipullo M, Bernasconi S, Corsello G. New insights in pediatrics in 2021: choices in allergy and immunology, critical care, endocrinology, gastroenterology, genetics, haematology, infectious diseases, neonatology, neurology, nutrition, palliative care, respiratory tract illnesses and telemedicine. Ital J Pediatr 2022;48:189. [PMID: 36435791 DOI: 10.1186/s13052-022-01374-8] [Reference Citation Analysis]
|
| 30 |
zhang S, Yao J, Bai X, Li L, Li S, Xu X, Sun Y, Xu C, Zhang H, Wang X. Bioinformatics analysis of gene expression network regulation in osteogenic differentiation of human bone marrow mesenchymal stem cells RunningTitle: Bioinformatics analysis of osteogenic differentiation.. [DOI: 10.21203/rs.3.rs-2156843/v1] [Reference Citation Analysis]
|
| 31 |
Pucci P, Lee L, Han M, Matthews J, Jahangiri L, Manners E, Sorby-adams A, Schlederer M, Kaggie J, Trigg R, Prokoph N, Ducray S, Merkel O, Rifatbegovic F, Luo J, Taschner-mandl S, Kenner L, Burke G, Turner S. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers collateral sensitivity to ALK inhibitors in high-risk neuroblastoma.. [DOI: 10.21203/rs.3.rs-2167328/v1] [Reference Citation Analysis]
|
| 32 |
Pulido R, Nunes-Xavier CE. Hopes on immunotherapy targeting B7-H3 in neuroblastoma. Transl Oncol 2022;27:101580. [PMID: 36327699 DOI: 10.1016/j.tranon.2022.101580] [Reference Citation Analysis]
|
| 33 |
Jin Q, Chen Y, Du S, Xu D, Yue J, Cai L, Yuan X. BCL11A Facilitates Cell Proliferation and Metastasis in Neuroblastoma via Regulating the PI3K/Akt Signaling Pathway. Curr Cancer Drug Targets 2022;22:919-30. [PMID: 35909289 DOI: 10.2174/1568009622666220728123748] [Reference Citation Analysis]
|
| 34 |
Zheng L, Shen L, Li Z, Zhang X, Wu M, Zhang Y, Liu J. Design, Preparation, and Evaluation of Osthol Poly-Butyl-Cyanoacrylate Nanoparticles with Improved In Vitro Anticancer Activity in Neuroblastoma Treatment. Molecules 2022;27. [PMID: 36296500 DOI: 10.3390/molecules27206908] [Reference Citation Analysis]
|
| 35 |
Tian XM, Xiang B, Yu YH, Li Q, Zhang ZX, Zhanghuang C, Jin LM, Wang JK, Mi T, Chen ML, Liu F, Wei GH. A novel cuproptosis-related subtypes and gene signature associates with immunophenotype and predicts prognosis accurately in neuroblastoma. Front Immunol 2022;13:999849. [PMID: 36211401 DOI: 10.3389/fimmu.2022.999849] [Reference Citation Analysis]
|
| 36 |
Shi X, Wang Y, Zhang L, Zhao W, Dai X, Yang Y, Zhang X. Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN. Front Cell Dev Biol 2022;10:1021820. [DOI: 10.3389/fcell.2022.1021820] [Reference Citation Analysis]
|
| 37 |
Chilamakuri R, Agarwal S. Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth. Current Oncology 2022;29:6508-6522. [DOI: 10.3390/curroncol29090512] [Reference Citation Analysis]
|
| 38 |
Rossi F, Tortora C, Paoletta M, Marrapodi MM, Argenziano M, Di Paola A, Pota E, Di Pinto D, Di Martino M, Iolascon G. Osteoporosis in Childhood Cancer Survivors: Physiopathology, Prevention, Therapy and Future Perspectives. Cancers 2022;14:4349. [DOI: 10.3390/cancers14184349] [Reference Citation Analysis]
|
| 39 |
Du X, Ding L, Huang S, Li F, Yan Y, Tang R, Ding X, Zhu Z, Wang W. Cathepsin L promotes chemresistance to neuroblastoma by modulating serglycin. Front Pharmacol 2022;13:920022. [DOI: 10.3389/fphar.2022.920022] [Reference Citation Analysis]
|
| 40 |
Arnaud-sampaio VF, Bento CA, Glaser T, Adinolfi E, Ulrich H, Lameu C. P2X7 receptor isoform B is a key drug resistance mediator for neuroblastoma. Front Oncol 2022;12:966404. [DOI: 10.3389/fonc.2022.966404] [Reference Citation Analysis]
|
| 41 |
Hu X, Liu R, Hou J, Peng W, Wan S, Xu M, Li Y, Zhang G, Zhai X, Liang P, Cui H. SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation. Oncogene 2022. [PMID: 35978151 DOI: 10.1038/s41388-022-02428-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 42 |
Liu N, Yang C, Yang L, Li T, Gong M, Wang H, Zhang J, Zhao H, Zou L, He X. Matrine induces autophagy in human neuroblastoma cells via blocking the AKT-mTOR pathway. Med Oncol 2022;39:167. [PMID: 35972593 DOI: 10.1007/s12032-022-01762-4] [Reference Citation Analysis]
|
| 43 |
Xu DL, Fan K, Zhang H, Tang LX, Wang Y, Xiang Z, Shi AM, Qu YC, Su CJ, Pan J. Anti-proliferation and apoptosis-inducing effects of dihydroartemisinin on SH-SY5Y cells and metabolomic analysis. Transl Pediatr 2022;11:1346-61. [PMID: 36072536 DOI: 10.21037/tp-22-331] [Reference Citation Analysis]
|
| 44 |
Yang Y, Zhao J, Zhang Y, Feng T, Yv B, Wang J, Gao Y, Yin M, Tang J, Li Y. MYCN protein stability is a better prognostic indicator in neuroblastoma. BMC Pediatr 2022;22:404. [PMID: 35820898 DOI: 10.1186/s12887-022-03449-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 45 |
Pereira M, Vale N. Saquinavir: From HIV to COVID-19 and Cancer Treatment. Biomolecules 2022;12:944. [DOI: 10.3390/biom12070944] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 46 |
Giljević JS, Rajačić N, Mikulić D, Batoš AT. Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia. Children 2022;9:943. [DOI: 10.3390/children9070943] [Reference Citation Analysis]
|
| 47 |
Jahangiri L. Profiling of the Prognostic Role of Extracellular Matrix-Related Genes in Neuroblastoma Using Databases and Integrated Bioinformatics. Onco 2022;2:85-112. [DOI: 10.3390/onco2020007] [Reference Citation Analysis]
|
| 48 |
Yin X, Lin H, Lin L, Miao L, He J, Zhuo Z. LncRNAs and CircRNAs in cancer. MedComm 2022;3. [DOI: 10.1002/mco2.141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 49 |
Peng J, Liu K, Cao L, Duan D, Song G, Liu S, Wang L, Li J, Zhang X, Huang K, Zhao Y, Niu Y, Han G. Adenoviral Vector for Enhanced Prostate Cancer Specific Transferrin Conjugated Drug Targeted Therapy. Nano Lett 2022. [PMID: 35522032 DOI: 10.1021/acs.nanolett.2c00931] [Reference Citation Analysis]
|
| 50 |
Li M, Wu S, Luo H, Niu J, Yan Y, Fang Y, Ke L, Chen W, Xu H, Li H, Hu X, Cao L, Chen Y, Tu H, He Y. Serological and Molecular Characterization of Hepatitis B Virus Infection in Gastric Cancer. Front Cell Infect Microbiol 2022;12:894836. [DOI: 10.3389/fcimb.2022.894836] [Reference Citation Analysis]
|
| 51 |
Zhu S, Wang H, Lv X, Wang J, Zhao H. Nanoscale Coordination Polymer Based on Bacterial Derivatives for Enhanced Radiotherapy in Neuroblastoma. NANO 2022;17:2250038. [DOI: 10.1142/s1793292022500382] [Reference Citation Analysis]
|
| 52 |
Park SY, Choi H, Chung JW. Reptiles as Promising Sources of Medicinal Natural Products for Cancer Therapeutic Drugs. Pharmaceutics 2022;14:874. [PMID: 35456708 DOI: 10.3390/pharmaceutics14040874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 53 |
Huang S, Gong N, Li J, Hong M, Li L, Zhang L, Zhang H. The role of ncRNAs in neuroblastoma: mechanisms, biomarkers and therapeutic targets. Biomark Res 2022;10:18. [PMID: 35392988 DOI: 10.1186/s40364-022-00368-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 54 |
Zhang Y, Hu R, Xi B, Nie D, Xu H, Liu A. Mechanisms of Senescence-Related NKG2D Ligands Release and Immune Escape Induced by Chemotherapy in Neuroblastoma Cells. Front Cell Dev Biol 2022;10:829404. [PMID: 35309907 DOI: 10.3389/fcell.2022.829404] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 55 |
Vasarri M, Vitale GA, Varese GC, Barletta E, D’auria MV, de Pascale D, Degl’innocenti D. Dihydroauroglaucin Isolated from the Mediterranean Sponge Grantia compressa Endophyte Marine Fungus Eurotium chevalieri Inhibits Migration of Human Neuroblastoma Cells. Pharmaceutics 2022;14:616. [DOI: 10.3390/pharmaceutics14030616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 56 |
Chilamakuri R, Agarwal S. Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth. Cancers (Basel) 2022;14:1067. [PMID: 35205815 DOI: 10.3390/cancers14041067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 57 |
Gatzweiler C, Ridinger J, Herter S, Gerloff XF, ElHarouni D, Berker Y, Imle R, Schmitt L, Kreth S, Stainczyk S, Ayhan S, Najafi S, Krunic D, Frese K, Meder B, Reuss D, Fiesel P, Schramm K, Blattner-Johnson M, Jones DTW, Banito A, Westermann F, Oppermann S, Milde T, Peterziel H, Witt O, Oehme I. Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models. Cancers (Basel) 2022;14:849. [PMID: 35159116 DOI: 10.3390/cancers14030849] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 58 |
Liu D, Tang X, Huang Z, Wen J, Zhou Y. Histone deacetylase HDAC2 regulates microRNA-125a expression in neuroblastoma. Brain Behav 2022;12:e2401. [PMID: 35060363 DOI: 10.1002/brb3.2401] [Reference Citation Analysis]
|
| 59 |
Huang C, He Y, Sun J, Yuan Q, Li S, Hou H, Su K, Ke C, Du Z, Yuan Z. Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma. Acta Histochem 2022;124:151856. [PMID: 35077998 DOI: 10.1016/j.acthis.2022.151856] [Reference Citation Analysis]
|
| 60 |
Caglar HO. Bioinformatics analysis of recurrent deletion regions in neuroblastoma. Med Oncol 2022;39. [DOI: 10.1007/s12032-021-01639-y] [Reference Citation Analysis]
|
| 61 |
Shen Q, Liu X, Li W, Zhao X, Li T, Zhou K, Zhou J. Emerging Role and Mechanism of circRNAs in Pediatric Malignant Solid Tumors. Front Genet 2022;12:820936. [DOI: 10.3389/fgene.2021.820936] [Reference Citation Analysis]
|
| 62 |
Zhong X, Zhang S, Zhang Y, Jiang Z, Li Y, Chang J, Niu J, Shi Y. HMGB3 is Associated With an Unfavorable Prognosis of Neuroblastoma and Promotes Tumor Progression by Mediating TPX2. Front Cell Dev Biol 2021;9:769547. [PMID: 34988076 DOI: 10.3389/fcell.2021.769547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 63 |
Metovic J, Napoli F, Osella-Abate S, Bertero L, Tampieri C, Orlando G, Bianchi M, Carli D, Fagioli F, Volante M, Papotti M. Overexpression of INSM1, NOTCH1, NEUROD1, and YAP1 genes is associated with adverse clinical outcome in pediatric neuroblastoma. Virchows Arch 2022;481:925-33. [PMID: 36121500 DOI: 10.1007/s00428-022-03406-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 64 |
Yang H, Yang J, Bian H, Wang X. A novel cuproptosis-related gene signature predicting overall survival in pediatric neuroblastoma patients. Front Pediatr 2022;10:1049858. [PMID: 36568423 DOI: 10.3389/fped.2022.1049858] [Reference Citation Analysis]
|
| 65 |
Patiño-Morales CC, Jaime-Cruz R, Sánchez-Gómez C, Corona JC, Hernández-Cruz EY, Kalinova-Jelezova I, Pedraza-Chaverri J, Maldonado PD, Silva-Islas CA, Salazar-García M. Antitumor Effects of Natural Compounds Derived from Allium sativum on Neuroblastoma: An Overview. Antioxidants (Basel) 2021;11:48. [PMID: 35052552 DOI: 10.3390/antiox11010048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 66 |
Chernysheva OO, Drui AE, Kachanov DY, Shamanskaya TV. Key genetic disorders in the pathogenesis of neuroblastoma. Voprosy gematologii/onkologii i immunopatologii v pediatrii 2021;20:178-184. [DOI: 10.24287/1726-1708-2021-20-4-178-184] [Reference Citation Analysis]
|
| 67 |
Lin L, Miao L, Lin H, Cheng J, Li M, Zhuo Z, He J. Targeting RAS in neuroblastoma: Is it possible? Pharmacol Ther 2021;236:108054. [PMID: 34915055 DOI: 10.1016/j.pharmthera.2021.108054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 68 |
Guan J, Hallberg B, Palmer RH. Chromosome Imbalances in Neuroblastoma-Recent Molecular Insight into Chromosome 1p-deletion, 2p-gain, and 11q-deletion Identifies New Friends and Foes for the Future. Cancers (Basel) 2021;13:5897. [PMID: 34885007 DOI: 10.3390/cancers13235897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 69 |
Musumeci F, Cianciusi A, D'Agostino I, Grossi G, Carbone A, Schenone S. Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma. Molecules 2021;26:7069. [PMID: 34885651 DOI: 10.3390/molecules26237069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 70 |
Ernsberger U, Deller T, Rohrer H. The sympathies of the body: functional organization and neuronal differentiation in the peripheral sympathetic nervous system. Cell Tissue Res 2021;386:455-75. [PMID: 34757495 DOI: 10.1007/s00441-021-03548-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 71 |
Li K, Yao T, Zhang Y, Li W, Wang Z. NEAT1 as a competing endogenous RNA in tumorigenesis of various cancers: Role, mechanism and therapeutic potential. Int J Biol Sci 2021;17:3428-40. [PMID: 34512157 DOI: 10.7150/ijbs.62728] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 72 |
Brenner AK, Gunnes MW. Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma-A Comprehensive Update. Pharmaceutics 2021;13:1427. [PMID: 34575503 DOI: 10.3390/pharmaceutics13091427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 73 |
Lu R, Jiang Y, Lai X, Liu S, Sun L, Zhou ZW. A Shortage of FTH Induces ROS and Sensitizes RAS-Proficient Neuroblastoma N2A Cells to Ferroptosis. Int J Mol Sci 2021;22:8898. [PMID: 34445601 DOI: 10.3390/ijms22168898] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 74 |
Uva P, Bosco MC, Eva A, Conte M, Garaventa A, Amoroso L, Cangelosi D. Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma. Cancers (Basel) 2021;13:2809. [PMID: 34199959 DOI: 10.3390/cancers13112809] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 75 |
Avery JT, Zhang R, Boohaker RJ. GLI1: A Therapeutic Target for Cancer. Front Oncol 2021;11:673154. [PMID: 34113570 DOI: 10.3389/fonc.2021.673154] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 76 |
Chen W, Hao X, Yang B, Zhang Y, Sun L, Hua Y, Yang L, Yu J, Zhao J, Hou L, Lu H. MYCN‑amplified neuroblastoma cell‑derived exosomal miR‑17‑5p promotes proliferation and migration of non‑MYCN amplified cells. Mol Med Rep 2021;23:245. [PMID: 33537818 DOI: 10.3892/mmr.2021.11884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 77 |
Zafar A, Wang W, Liu G, Wang X, Xian W, McKeon F, Foster J, Zhou J, Zhang R. Molecular targeting therapies for neuroblastoma: Progress and challenges. Med Res Rev 2021;41:961-1021. [PMID: 33155698 DOI: 10.1002/med.21750] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 13.7] [Reference Citation Analysis]
|
